📊 WHWK Key Takeaways
Is Whitehawk Therapeutics, Inc. (WHWK) a Good Investment?
Whitehawk Therapeutics exhibits fundamental deterioration with zero revenue, -$23.5M operating losses, and -$22.2M quarterly cash burn with limited runway (~2 quarters) from $34.8M cash reserves. Despite a strong balance sheet and minimal debt, the company faces existential execution risk as a pre-revenue pharmaceutical with no commercial traction and mounting losses.
Why Buy Whitehawk Therapeutics, Inc. Stock? WHWK Key Strengths
- Strong balance sheet with $34.8M cash and $116.2M stockholders equity
- Zero debt with 0.00 Debt/Equity ratio and high liquidity ratios (11.36x current ratio)
- Low liabilities at $11.1M relative to total assets of $127.2M
WHWK Stock Risks: Whitehawk Therapeutics, Inc. Investment Risks
- Zero revenue (-72.5% YoY) indicating failed or absent commercialization
- Unsustainable cash burn of -$22.2M per period with approximately 1.5-2 quarters of runway remaining
- Significant insider activity (14 Form 4 filings in 90 days) suggesting potential concerns from company insiders
- Negative profitability with -$23.5M operating income and -17.4% ROA
- Pre-revenue biotech model carries extreme execution risk with no proven commercial success
Key Metrics to Watch
- Quarterly cash burn rate and total cash runway estimates
- Revenue generation timeline and commercialization milestones
- R&D pipeline progress and clinical trial developments
Whitehawk Therapeutics, Inc. (WHWK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.36x current ratio provides a solid financial cushion.
WHWK Profit Margin, ROE & Profitability Analysis
WHWK vs Healthcare Sector: How Whitehawk Therapeutics, Inc. Compares
How Whitehawk Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Whitehawk Therapeutics, Inc. Stock Overvalued? WHWK Valuation Analysis 2026
Based on fundamental analysis, Whitehawk Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Whitehawk Therapeutics, Inc. Balance Sheet: WHWK Debt, Cash & Liquidity
WHWK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Whitehawk Therapeutics, Inc.'s revenue has grown significantly by 78% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.36 indicates the company is currently unprofitable.
WHWK Revenue Growth, EPS Growth & YoY Performance
WHWK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$22.2M | $-0.32 |
| Q3 2025 | N/A | $2.7M | $0.04 |
| Q2 2025 | N/A | -$14.6M | $0.37 |
| Q1 2025 | $5.4M | -$18.3M | $-0.68 |
| Q3 2024 | $6.0M | -$12.5M | $-0.46 |
| Q2 2024 | $6.2M | -$14.6M | $-0.54 |
| Q1 2024 | $5.4M | -$15.2M | $-0.57 |
| Q3 2023 | $4.2M | -$13.9M | $-0.60 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Whitehawk Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
WHWK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Whitehawk Therapeutics, Inc. (CIK: 0001422142)
📋 Recent SEC Filings
❓ Frequently Asked Questions about WHWK
What is the AI rating for WHWK?
Whitehawk Therapeutics, Inc. (WHWK) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are WHWK's key strengths?
Claude: Strong balance sheet with $34.8M cash and $116.2M stockholders equity. Zero debt with 0.00 Debt/Equity ratio and high liquidity ratios (11.36x current ratio).
What are the risks of investing in WHWK?
Claude: Zero revenue (-72.5% YoY) indicating failed or absent commercialization. Unsustainable cash burn of -$22.2M per period with approximately 1.5-2 quarters of runway remaining.
What is WHWK's revenue and growth?
Whitehawk Therapeutics, Inc. reported revenue of $0.0.
Does WHWK pay dividends?
Whitehawk Therapeutics, Inc. does not currently pay dividends.
Where can I find WHWK SEC filings?
Official SEC filings for Whitehawk Therapeutics, Inc. (CIK: 0001422142) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is WHWK's EPS?
Whitehawk Therapeutics, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is WHWK a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Whitehawk Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is WHWK stock overvalued or undervalued?
Valuation metrics for WHWK: ROE of -19.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy WHWK stock in 2026?
Our dual AI analysis gives Whitehawk Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is WHWK's free cash flow?
Whitehawk Therapeutics, Inc.'s operating cash flow is $-22.2M, with capital expenditures of $0.0.
How does WHWK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -19.1% (avg: 15%), current ratio 11.36 (avg: 2).